Teleflex Incorporated: peers
Teleflex Incorporated beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Teleflex Incorporatedbase TFX · 🇺🇸 US Percentile in Healthcare Percentile in USA | Merit Medical Systems, Inc. MMSI · 🇺🇸 US Percentile in Healthcare Percentile in USA | Haemonetics Corporation HAE · 🇺🇸 US Percentile in Healthcare Percentile in USA | iRhythm Technologies, Inc. IRTC · 🇺🇸 US Percentile in Healthcare Percentile in USA | ICU Medical, Inc. ICUI · 🇺🇸 US Percentile in Healthcare Percentile in USA | Pulse Biosciences, Inc. PLSE · 🇺🇸 US Percentile in Healthcare Percentile in USA | Envista Holdings Corporation NVST · 🇺🇸 US Percentile in Healthcare Percentile in USA | AtriCure, Inc. ATRC · 🇺🇸 US Percentile in Healthcare Percentile in USA | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $5.5 BOct 28, 2026 · Market data2nd of 8 | $5.6 BOct 26, 2026 · Market data1st of 8 | $5.5 BOct 28, 2026 · Market data3rd of 8 | $4.3 BOct 30, 2026 · Market data4th of 8 | $3.9 BOct 9, 2026 · Market data5th of 8 | $3.9 BOct 27, 2026 · Market data6th of 8 | $3.8 BOct 28, 2026 · Market data7th of 8 | $3.1 BOct 29, 2026 · Market data8th of 8 | $4.1 B8 ranked |
| Revenue (Better neither way: ranked highest first) | $2.0 BFY2025 · SEC3rd of 8 | $1.5 BFY2025 · SEC4th of 8 | $1.3 BFY2025 · SEC5th of 8 | $747 MFY2025 · SEC6th of 8 | $2.2 BFY2025 · SEC2nd of 8 | $0 MFY2025 · SEC8th of 8 | $2.7 BFY2025 · SEC1st of 8 | $535 MFY2025 · SEC7th of 8 | $1.4 B8 ranked |
| Net income (Higher is better) | $-906 MFY2025 · SEC8th of 8 | $128 MFY2025 · SEC1st of 8 | $97 MFY2025 · SEC2nd of 8 | $-45 MFY2025 · SEC6th of 8 | $1 MFY2025 · SEC4th of 8 | $-73 MFY2025 · SEC7th of 8 | $47 MFY2025 · SEC3rd of 8 | $-11 MFY2025 · SEC5th of 8 | $-5 M8 ranked |
| Employees (Better neither way: ranked highest first) | 15,500As on 2022 · Profile1st of 7 | 6,446As on 2021 · Profile4th of 7 | 3,034As on 2022 · Profile5th of 7 | 1,700As on 2021 · Profile6th of 7 | 8,500As on 2021 · Profile3rd of 7 | —— | 12,700As on 2022 · Profile2nd of 7 | 875As on 2021 · Profile7th of 7 | 6,4467 ranked |
| Growth | |||||||||
| Market cap change, 30 days (Higher is better) | —— | +6.6%30 days to Oct 26, 2026 · Market data1st of 2 | —— | —— | —— | —— | -2.0%30 days to Oct 28, 2026 · Market data2nd of 2 | —— | +2.3%2 ranked |
| Revenue growth (Higher is better) | +17.3%FY2025 · SEC2nd of 763rd75th | +11.8%FY2025 · SEC4th of 754th65th | -2.0%FY2025 · SEC6th of 722nd24th | +26.2%FY2025 · SEC1st of 774th84th | -6.3%FY2025 · SEC7th of 716th16th | ———— | +8.3%FY2025 · SEC5th of 746th56th | +14.9%FY2025 · SEC3rd of 759th71st | +11.8%7 ranked |
| Revenue growth, 3 years a year (Higher is better) | -10.6%FY2025 · SEC7th of 711th10th | +9.6%FY2025 · SEC3rd of 752nd68th | +4.5%FY2025 · SEC4th of 740th51st | +22.1%FY2025 · SEC1st of 774th87th | -0.7%FY2025 · SEC6th of 725th30th | ———— | +1.9%FY2025 · SEC5th of 732nd40th | +17.4%FY2025 · SEC2nd of 768th82nd | +4.5%7 ranked |
| Earnings per share growth (Higher is better) | ———— | +4.9%FY2025 · SEC1st of 244th44th | -38.1%FY2025 · SEC2nd of 213th13th | ———— | ———— | ———— | ———— | ———— | -16.6%2 ranked |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | 56.2%FY2025 · SEC4th of 746th70th | 48.7%FY2025 · SEC6th of 734th62nd | 59.0%FY2025 · SEC3rd of 751st73rd | 70.6%FY2025 · SEC2nd of 769th83rd | 36.8%FY2025 · SEC7th of 722nd46th | ———— | 54.7%FY2025 · SEC5th of 743rd68th | 75.0%FY2025 · SEC1st of 775th87th | 56.2%7 ranked |
| Operating margin (Higher is better) | 5.9%FY2025 · SEC4th of 766th58th | 12.2%FY2025 · SEC1st of 776th73rd | 11.8%FY2025 · SEC2nd of 776th72nd | -7.7%FY2025 · SEC7th of 750th29th | 1.9%FY2025 · SEC5th of 761st45th | ———— | 8.0%FY2025 · SEC3rd of 769th63rd | -1.8%FY2025 · SEC6th of 755th37th | 5.9%7 ranked |
| Net margin (Higher is better) | -45.5%FY2025 · SEC7th of 732nd15th | 8.5%FY2025 · SEC1st of 776th71st | 7.3%FY2025 · SEC2nd of 774th68th | -6.0%FY2025 · SEC6th of 752nd32nd | 0.0%FY2025 · SEC4th of 760th43rd | ———— | 1.7%FY2025 · SEC3rd of 764th49th | -2.1%FY2025 · SEC5th of 757th38th | 0.0%7 ranked |
| Free cash flow margin (Higher is better) | 0.1%FY2025 · SEC7th of 752nd34th | 14.2%FY2025 · SEC2nd of 780th79th | 19.5%FY2025 · SEC1st of 787th87th | 4.6%FY2025 · SEC5th of 762nd52nd | 4.1%FY2025 · SEC6th of 761st50th | ———— | 8.5%FY2025 · SEC4th of 768th66th | 9.0%FY2025 · SEC3rd of 770th68th | 8.5%7 ranked |
| Return on equity (Higher is better) | -24.5%FY2025 · SEC6th of 858th26th | 8.7%FY2025 · SEC2nd of 879th60th | 12.0%FY2025 · SEC1st of 884th71st | -36.6%FY2025 · SEC7th of 850th22nd | 0.0%FY2025 · SEC4th of 873rd42nd | -74.5%FY2025 · SEC8th of 832nd14th | 1.6%FY2025 · SEC3rd of 874th44th | -2.4%FY2025 · SEC5th of 871st39th | -1.2%8 ranked |
| Return on invested capital (Higher is better) | ———— | 7.7%FY2025 · SEC1st of 328th32nd | 6.8%FY2025 · SEC2nd of 327th28th | ———— | 0.6%FY2025 · SEC3rd of 35th2nd | ———— | ———— | ———— | 6.8%3 ranked |
| Valuation | |||||||||
| P/E ratio (Better neither way: ranked highest first) | 18.1×price Oct 28, 2026 · Market data5th of 627th47th | 34.9×price Oct 26, 2026 · Market data4th of 654th78th | 52.6×price Oct 28, 2026 · Market data3rd of 673rd88th | ———— | 65.2×price Oct 9, 2026 · Market data2nd of 679th91st | ———— | 6.0×price Oct 28, 2026 · Market data6th of 67th6th | 210.1×price Oct 29, 2026 · Market data1st of 696th97th | 43.7×6 ranked |
| Price to sales (Better neither way: ranked highest first) | 2.4×price Oct 28, 2026 · Market data5th of 739th53rd | 3.5×price Oct 26, 2026 · Market data4th of 749th66th | 4.0×price Oct 28, 2026 · Market data3rd of 751st71st | 5.0×price Oct 30, 2026 · Market data2nd of 757th77th | 1.8×price Oct 9, 2026 · Market data6th of 731st45th | ———— | 1.3×price Oct 28, 2026 · Market data7th of 722nd36th | 5.3×price Oct 29, 2026 · Market data1st of 758th78th | 3.5×7 ranked |
| Price to book (Better neither way: ranked highest first) | 1.8×price Oct 28, 2026 · Market data7th of 835th43rd | 3.5×price Oct 26, 2026 · Market data5th of 856th67th | 6.9×price Oct 28, 2026 · Market data3rd of 876th83rd | 28.1×price Oct 30, 2026 · Market data2nd of 895th97th | 1.9×price Oct 9, 2026 · Market data6th of 836th44th | 48.0×price Oct 27, 2026 · Market data1st of 898th98th | 1.2×price Oct 28, 2026 · Market data8th of 823rd28th | 6.4×price Oct 29, 2026 · Market data4th of 873rd81st | 4.9×8 ranked |
| Free cash flow yield (Higher is better) | 0.0%price Oct 28, 2026 · Market data7th of 868th37th | 3.9%price Oct 26, 2026 · Market data3rd of 882nd59th | 4.8%price Oct 28, 2026 · Market data2nd of 886th65th | 0.8%price Oct 30, 2026 · Market data6th of 871st40th | 2.3%price Oct 9, 2026 · Market data4th of 876th48th | -1.4%price Oct 27, 2026 · Market data8th of 863rd33rd | 6.1%price Oct 28, 2026 · Market data1st of 890th72nd | 1.5%price Oct 29, 2026 · Market data5th of 874th44th | 1.9%8 ranked |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | 0.8×FY2025 · SEC5th of 671st62nd | 0.5×FY2025 · SEC2nd of 652nd41st | 1.6×FY2025 · SEC6th of 686th81st | ———— | 0.6×FY2025 · SEC4th of 660th50th | ———— | 0.5×FY2025 · SEC3rd of 652nd42nd | 0.1×FY2025 · SEC1st of 625th18th | 0.5×6 ranked |
| Net debt to EBITDA (Lower is better) | 7.6×FY2025 · SEC5th of 593rd91st | 0.9×FY2025 · SEC2nd of 539th33rd | 3.7×FY2025 · SEC3rd of 576th70th | ———— | 3.9×FY2025 · SEC4th of 577th72nd | ———— | 0.7×FY2025 · SEC1st of 537th30th | ———— | 3.7×5 ranked |
| Interest cover (Higher is better) | ———— | ———— | 8.1×FY2025 · SEC1st of 289th80th | ———— | 0.5×FY2025 · SEC2nd of 272nd49th | ———— | ———— | ———— | 4.3×2 ranked |
| Piotroski F-score (Higher is better) | 5 of 9FY2025 · SEC6th of 6 | 7 of 9FY2025 · SEC1st of 6 | 7 of 9FY2025 · SEC1st of 6 | —— | 6 of 9FY2025 · SEC5th of 6 | —— | 7 of 9FY2025 · SEC1st of 6 | 7 of 9FY2025 · SEC1st of 6 | 7.0 of 96 ranked |
| Scorecard | |||||||||
| Scorecard (Higher is better) | 12 of 27FY2025 · Scorecard4th of 8 | 17 of 24FY2025 · Scorecard1st of 8 | 12 of 27FY2025 · Scorecard4th of 8 | 7 of 21FY2025 · Scorecard7th of 8 | 10 of 27FY2025 · Scorecard6th of 8 | 1 of 10FY2025 · Scorecard8th of 8 | 15 of 23FY2025 · Scorecard2nd of 8 | 12 of 23FY2025 · Scorecard3rd of 8 | 44% passed8 ranked |
| Valuation checks (Higher is better) | 4 of 6FY2025 · Scorecard2nd of 8 | 1 of 6FY2025 · Scorecard4th of 8 | 0 of 6FY2025 · Scorecard5th of 8 | 0 of 5FY2025 · Scorecard5th of 8 | 2 of 6FY2025 · Scorecard3rd of 8 | 0 of 4FY2025 · Scorecard5th of 8 | 5 of 6FY2025 · Scorecard1st of 8 | 0 of 6FY2025 · Scorecard5th of 8 | 8% passed8 ranked |
| Growth checks (Higher is better) | 1 of 6FY2025 · Scorecard6th of 8 | 6 of 6FY2025 · Scorecard1st of 8 | 2 of 6FY2025 · Scorecard5th of 8 | 4 of 6FY2025 · Scorecard3rd of 8 | 1 of 6FY2025 · Scorecard6th of 8 | 0 of 1FY2025 · Scorecard8th of 8 | 3 of 6FY2025 · Scorecard4th of 8 | 5 of 6FY2025 · Scorecard2nd of 8 | 42% passed8 ranked |
| Profitability checks (Higher is better) | 0 of 5FY2025 · Scorecard7th of 8 | 4 of 6FY2025 · Scorecard1st of 8 | 3 of 6FY2025 · Scorecard2nd of 8 | 1 of 5FY2025 · Scorecard5th of 8 | 2 of 6FY2025 · Scorecard4th of 8 | 0 of 3FY2025 · Scorecard7th of 8 | 2 of 5FY2025 · Scorecard3rd of 8 | 1 of 5FY2025 · Scorecard5th of 8 | 27% passed8 ranked |
| Financial health checks (Higher is better) | 4 of 5FY2025 · Scorecard3rd of 8 | 5 of 5FY2025 · Scorecard1st of 8 | 4 of 6FY2025 · Scorecard5th of 8 | 2 of 3FY2025 · Scorecard5th of 8 | 4 of 6FY2025 · Scorecard5th of 8 | 1 of 2FY2025 · Scorecard8th of 8 | 4 of 5FY2025 · Scorecard3rd of 8 | 5 of 5FY2025 · Scorecard1st of 8 | 73% passed8 ranked |
| Shareholder returns checks (Higher is better) | 3 of 5FY2025 · Scorecard5th of 7 | 1 of 1FY2025 · Scorecard1st of 7 | 3 of 3FY2025 · Scorecard1st of 7 | 0 of 2FY2025 · Scorecard7th of 7 | 1 of 3FY2025 · Scorecard6th of 7 | —— | 1 of 1FY2025 · Scorecard1st of 7 | 1 of 1FY2025 · Scorecard1st of 7 | 100% passed7 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | 115.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 8 | 104.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 8 | 107.9%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 8 | 107.4%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 8 | 101.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 8 | 20.9%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 8 | 124.9%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 8 | 105.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 8 | 106.6%8 ranked |
| Institutions holding (Better neither way: ranked highest first) | 3882026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 8 | 4242026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 8 | 3582026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 8 | 3212026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 8 | 3122026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 8 | 1422026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 8 | 4102026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 8 | 2862026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 8 | 3408 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | +5.0 pp2026-Q2 against 2026-Q1 · 13F4th of 8 | +5.3 pp2026-Q2 against 2026-Q1 · 13F2nd of 8 | +4.8 pp2026-Q2 against 2026-Q1 · 13F5th of 8 | +0.1 pp2026-Q2 against 2026-Q1 · 13F8th of 8 | +4.1 pp2026-Q2 against 2026-Q1 · 13F6th of 8 | +3.6 pp2026-Q2 against 2026-Q1 · 13F7th of 8 | +8.8 pp2026-Q2 against 2026-Q1 · 13F1st of 8 | +5.2 pp2026-Q2 against 2026-Q1 · 13F3rd of 8 | +4.9 pp8 ranked |
| Dividends | |||||||||
| Dividend yield (Higher is better) | 1.1%FY2025 · SEConly one with it54th28th | ———— | ———— | ———— | ———— | ———— | ———— | ———— | 1.1%— |
| Shareholder yield (Higher is better) | 6.5%FY2025 · SEC1st of 480th77th | ———— | 3.2%FY2025 · SEC2nd of 462nd51st | 0.0%FY2025 · SEC4th of 47th3rd | 0.2%FY2025 · SEC3rd of 419th10th | ———— | ———— | ———— | 1.7%4 ranked |
| Dividend per share (Better neither way: ranked highest first) | $1.36FY2025 · SEConly one with it | —— | —— | —— | —— | —— | —— | —— | $1.36— |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Teleflex Incorporated: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Merit Medical Systems, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Haemonetics Corporation: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; iRhythm Technologies, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; ICU Medical, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Pulse Biosciences, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Envista Holdings Corporation: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; AtriCure, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Teleflex Incorporated | 5.9%FY2025 | 66th percentile in Healthcaremedian -7.7%, 674 companies | 58th percentile in USAmedian 3.5%, 2,595 companies |
| Merit Medical Systems, Inc. | 12.2%FY2025 | 76th percentile in Healthcaremedian -7.7%, 674 companies | 73rd percentile in USAmedian 3.5%, 2,595 companies |
| Haemonetics Corporation | 11.8%FY2025 | 76th percentile in Healthcaremedian -7.7%, 674 companies | 72nd percentile in USAmedian 3.5%, 2,595 companies |
| iRhythm Technologies, Inc. | -7.7%FY2025 | 50th percentile in Healthcaremedian -7.7%, 674 companies | 29th percentile in USAmedian 3.5%, 2,595 companies |
| ICU Medical, Inc. | 1.9%FY2025 | 61st percentile in Healthcaremedian -7.7%, 674 companies | 45th percentile in USAmedian 3.5%, 2,595 companies |
| Pulse Biosciences, Inc. | — | — | — |
| Envista Holdings Corporation | 8.0%FY2025 | 69th percentile in Healthcaremedian -7.7%, 674 companies | 63rd percentile in USAmedian 3.5%, 2,595 companies |
| AtriCure, Inc. | -1.8%FY2025 | 55th percentile in Healthcaremedian -7.7%, 674 companies | 37th percentile in USAmedian 3.5%, 2,595 companies |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | Teleflex Incorporated | Merit Medical Systems, Inc. | Haemonetics Corporation | iRhythm Technologies, Inc. | ICU Medical, Inc. | Pulse Biosciences, Inc. | Envista Holdings Corporation | AtriCure, Inc. |
|---|---|---|---|---|---|---|---|---|
| 2025 | $2.0 BSEC3rd | $1.5 BSEC4th | $1.3 BSEC5th | $747 MSEC6th | $2.2 BSEC2nd | $0 MSEC8th | $2.7 BSEC1st | $535 MSEC7th |
| 2024 | $1.7 BSEC3rd | $1.4 BSEC5th | $1.4 BSEC4th | $592 MSEC6th | $2.4 BSEC2nd | — | $2.5 BSEC1st | $465 MSEC7th |
| 2023 | $1.7 BSEC3rd | $1.3 BSEC5th | $1.3 BSEC4th | $493 MSEC6th | $2.3 BSEC2nd | — | $2.6 BSEC1st | $399 MSEC7th |
| 2022 | $2.8 BSEC1st | $1.2 BSEC5th | $1.2 BSEC4th | $411 MSEC6th | $2.3 BSEC3rd | $1 MSEC8th | $2.6 BSEC2nd | $330 MSEC7th |
| 2021 | $2.8 BSEC1st | $1.1 BSEC4th | $993 MSEC5th | $323 MSEC6th | $1.3 BSEC3rd | $1 MSEC8th | $2.5 BSEC2nd | $274 MSEC7th |
| 2020 | $2.5 BSEC1st | $964 MSEC4th | $870 MSEC5th | $265 MSEC6th | $1.3 BSEC3rd | — | $1.9 BSEC2nd | $207 MSEC7th |
| 2019 | $2.6 BSEC1st | $995 MSEC4th | $988 MSEC5th | $215 MSEC7th | $1.3 BSEC3rd | — | $2.3 BSEC2nd | $231 MSEC6th |
| 2018 | $2.4 BSEC2nd | $883 MSEC5th | $968 MSEC4th | $147 MSEC7th | $1.4 BSEC3rd | — | $2.8 BSEC1st | $202 MSEC6th |
| 2017 | $2.1 BSEC2nd | $728 MSEC5th | $904 MSEC4th | $99 MSEC7th | $1.3 BSEC3rd | — | $2.8 BSEC1st | $175 MSEC6th |
| 2016 | $1.9 BSEC1st | $604 MSEC3rd | $886 MSEC2nd | $64 MSEC6th | $379 MSEC4th | — | — | $155 MSEC5th |
| 2015 | $1.8 BSEC1st | $542 MSEC3rd | $909 MSEC2nd | $36 MSEC6th | $342 MSEC4th | — | — | $130 MSEC5th |
| 2014 | $1.8 BSEC1st | $510 MSEC3rd | $910 MSEC2nd | $22 MSEC6th | $309 MSEC4th | — | — | $107 MSEC5th |
Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Teleflex Incorporated#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Merit Medical Systems, Inc.MMSI · 🇺🇸 USASame industry: Medical Instruments · Similar size: $5.6 B market cap against $5.5 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $5.6 B (Oct 26, 2026) · revenue $1.5 B (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Haemonetics CorporationHAE · 🇺🇸 USASame industry: Medical Instruments · Similar size: $5.5 B market cap against $5.5 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $5.5 B (Oct 28, 2026) · revenue $1.3 B (year to March 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- iRhythm Technologies, Inc.IRTC · 🇺🇸 USASame industry: Medical Instruments · Similar size: $4.3 B market cap against $5.5 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $4.3 B (Oct 30, 2026) · revenue $747 M (year to December 2025)98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)In the group
- ICU Medical, Inc.ICUI · 🇺🇸 USASame industry: Medical Instruments · Similar size: $3.9 B market cap against $5.5 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $3.9 B (Oct 9, 2026) · revenue $2.2 B (year to December 2025)98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)In the group
- Pulse Biosciences, Inc.PLSE · 🇺🇸 USASame industry: Medical Instruments · Similar size: $3.9 B market cap against $5.5 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $3.9 B (Oct 27, 2026) · revenue $0 M (year to December 2025)98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)In the group
- Envista Holdings CorporationNVST · 🇺🇸 USASame industry: Medical Instruments · Similar size: $3.8 B market cap against $5.5 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $3.8 B (Oct 28, 2026) · revenue $2.7 B (year to December 2025)98 of 100 (industry or sector 50 + size 28 + country 15 + figures on file 5)In the group
- AtriCure, Inc.ATRC · 🇺🇸 USASame industry: Medical Instruments · Similar size: $3.1 B market cap against $5.5 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $3.1 B (Oct 29, 2026) · revenue $535 M (year to December 2025)96 of 100 (industry or sector 50 + size 26 + country 15 + figures on file 5)In the group
- The Cooper Companies, Inc.COO · 🇺🇸 USASame industry: Medical Instruments · Similar size: $11.3 B market cap against $5.5 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $11.3 B (Oct 29, 2026) · revenue $4.1 B (year to October 2025)95 of 100 (industry or sector 50 + size 25 + country 15 + figures on file 5)+ Add
- Repligen CorporationRGEN · 🇺🇸 USASame industry: Medical Instruments · Similar size: $11.5 B market cap against $5.5 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $11.5 B (Oct 27, 2026) · revenue $738 M (year to December 2025)95 of 100 (industry or sector 50 + size 25 + country 15 + figures on file 5)+ Add
- Baxter International Inc.BAX · 🇺🇸 USASame industry: Medical Instruments · Similar size: $12.9 B market cap against $5.5 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $12.9 B (Oct 28, 2026) · revenue $11.2 B (year to December 2025)94 of 100 (industry or sector 50 + size 25 + country 15 + figures on file 5)+ Add
- Glaukos CorporationGKOS · 🇺🇸 USASame industry: Medical Instruments · Similar size: $14.4 B market cap against $5.5 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $14.4 B (Oct 30, 2026) · revenue $507 M (year to December 2025)94 of 100 (industry or sector 50 + size 24 + country 15 + figures on file 5)+ Add
- LeMaitre Vascular, Inc.LMAT · 🇺🇸 USASame industry: Medical Instruments · Similar size: $1.9 B market cap against $5.5 B · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $1.9 B (Oct 22, 2026) · revenue $250 M (year to December 2025)93 of 100 (industry or sector 50 + size 23 + country 15 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.